Granules India share price declined in the early trade on June 23 after the company received one observation from USFDA for its Hyderabad facility.
At 09:21am, Granules India was quoting at Rs 483.45, down Rs 3.40, or 0.70 percent, on the BSE.
".... API Unit-I facility located at Bonthapally Village, Sangareddy District, Hyderabad, Telangana, India has completed a USFDA inspection from June 16, 2025 to June 20, 2025 with one 483 observation," company said.
The company will respond to this observation within the stipulated time, it added.
Bonthapally facility is one of the world’s largest single-site Paracetamol API manufacturing plants by volume. Along with Paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility.
Catch all the market action on our live blog
The share touched a 52-week high of Rs 724.55 and a 52-week low of Rs 412.05 on 02 September, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 33.28 percent below its 52-week high and 17.33 percent above its 52-week low.
The market capitalisation of the company stands at Rs 11,730.61 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
